Inhibitory effect of dexamethasone on residual Lewis lung cancer cells in mice following palliative surgery

Sun,Ningbo; Ji,Huaijun; Wang,Wei; Zhu,Qiang; Cao,Ming; Zang,Qi

doi:10.3892/ol.2016.5422

Inhibitory effect of dexamethasone on residual Lewis lung cancer cells in mice following palliative surgery

Authors:
- Ningbo Sun
- Huaijun Ji
- Wei Wang
- Qiang Zhu
- Ming Cao
- Qi Zang
View Affiliations

Affiliations: Department of Cardiac Surgery, Shengli Oilfield Central Hospital, Dongying, Shandong 257034, P.R. China, Surgery Division, Graduate Department, Weifang Medical College, Weifang, Shandong 261031, P.R. China, Department of Thoracic Surgery, Qianfoshan Hospital Affiliated to Shandong University, Jinan, Shandong 250014, P.R. China
Published online on: November 23, 2016 https://doi.org/10.3892/ol.2016.5422
Pages: 356-362

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Previous studies found that glucocorticoids were closely associated with the oncogenesis and development of numerous types of tumors. The aim of the present study was to investigate the effect of dexamethasone on the growth and angiogenesis of Lewis lung cancer cells in mice who received palliative surgery. Lewis lung carcinoma cells were inoculated subcutaneously into the right axilla of C57BL/6 mice. When tumor diameter reached 0.5 cm, 2 weeks later, palliative surgery was performed, and the mice were randomly divided into 3 groups with 6 animals in each group (control group, cisplatin group and dexamethasone group). From the first postoperative day, all the mice were administered with saline, cisplatin or dexamethasone for 10 days, and changes in xenograft tumor volumes were monitored. Cisplatin and dexamethasone were dissolved in normal saline (0.9%). All mice were sacrificed on postoperative day 11, and the whole body and the local tumors were weighed immediately. The expression levels of hypoxia inducible factor 1α (HIF‑1α), vascular endothelial growth factor (VEGF), proliferating cell nuclear antigen and the microvessel density (MVD) in the tumor mass, were measured by immunohistochemistry, western blotting and quantitative polymerase chain reaction. In the present study, tumor growth was inhibited in the cisplatin group and dexamethasone group, and the weights of tumors were significantly decreased in the cisplatin group and dexamethasone group compared with the control group (P<0.001). The expression levels of HIF‑1α and VEGF and the MVD were significantly lower in the cisplatin group and dexamethasone group than in the control group (P<0.01). In conclusion, dexamethasone can inhibit the growth and angiogenesis of residual Lewis lung carcinoma subsequent to palliative surgery partially through downregulation of HIF‑1α and VEGF signaling pathways.

View Figures

View References

1	Reck M, Heigener DF, Mok T, Soria JC and Rabe KF: Management of non-small-cell lung cancer: Recent developments. Lancet. 382:709–719. 2013. View Article : Google Scholar : PubMed/NCBI
2	Barnes PJ: Anti-inflammatory actions of glucocorticoids: Molecular mechanisms. Clin Sci. 94:557–572. 1998. View Article : Google Scholar : PubMed/NCBI
3	Machein MR, Kullmer J, Ronicke V, Machein U, Krieg M, Damert A, Breier G, Risau W and Plate KH: Differential downregulation of vascular endothelial growth factor by dexamethasone in normoxic and hypoxic rat glioma cells. Neuropathol Appl Neurobiol. 25:104–112. 1999. View Article : Google Scholar : PubMed/NCBI
4	Nauck M, Karakiulakis G, Perruchoud AP, Papakonstantinou E and Roth M: Corticosteroids inhibit the expression of the vascular endothelial growth factor gene in human vascular smooth muscle cells. Eur J Pharmacol. 341:309–315. 1998. View Article : Google Scholar : PubMed/NCBI
5	Rutz HP: Effects of corticosteroid use on treatment of solid tumours. Lancet. 360:1969–1970. 2002. View Article : Google Scholar : PubMed/NCBI
6	Wang H, Wang Y, Rayburn ER, Hill DL, Rinehart JJ and Zhang R: Dexcamethasone as a chemosensitizer for breast cancer chemotherapy: Potentiation of the antitumor activity of adriamycin, modulation of cytokine expression, and pharmacokinetics. Int J Oncol. 30:947–953. 2007.PubMed/NCBI
7	Arafa HM, Abdel-Hamid MA, El-Khouly AA, Elmazar MM and Osman AM: Enhancement by dexamethasone of the therapeutic benefits of cisplatin via regulation of tumor angiogenesis and cell cycle kinetics in a murine tumor paradigm. Toxicology. 222:103–113. 2006. View Article : Google Scholar : PubMed/NCBI
8	Yemelyanov A, Czwornog J, Gera L, Joshi S, Chatterton RT Jr and Budunova I: Novel steroid receptor phyto-modulator compound a inhibits growth and survival of prostate cancer cells. Cancer Res. 68:4763–4773. 2008. View Article : Google Scholar : PubMed/NCBI
9	Moghaddam SJ, Haghighi EN, Samiee S, Shahid N, Keramati AR, Dadgar S and Zali MR: Immunohistochemical analysis of p53, cyclinD1, RB1, c-fos and N-ras gene expression in hepatocellular carcinoma in Iran. World J Gastroenterol. 13:588–593. 2007. View Article : Google Scholar : PubMed/NCBI
10	Mamori S, Nagatsuma K, Matsuura T, Ohkawa K, Hano H, Fukunaga M, Matsushima M, Masui Y, Fushiya N, Onoda H, et al: Useful detection of CD147 (EMMPRIN) for pathological diagnosis of early hepatocellular carcinoma in needle biopsy samples. World J Gastroenterol. 13:2913–2917. 2007. View Article : Google Scholar : PubMed/NCBI
11	Vermeulen PB, Gasparini G, Fox SB, Toi M, Martin L, McCulloch P, Pezzella F, Viale G, Weidner N, Harris AL and Dirix LY: Quantification of angiogenesis in solid human tumours: An international consensus on the methodology and criteria of evaluation. Eur J Cancer 32A. 2474–2484. 1996. View Article : Google Scholar
12	Pfaffl MW: A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res. 29:e452001. View Article : Google Scholar : PubMed/NCBI
13	Folkman J: What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst. 82:4–6. 1990. View Article : Google Scholar : PubMed/NCBI
14	Yano T, Tanikawa S, Fujie T, Masutani M and Horie T: Vascular endothelial growth factor expression and neovascularisation in non-small cell lung cancer. Eur J Cancer. 36:601–609. 2000. View Article : Google Scholar : PubMed/NCBI
15	Wang GL and Semenza GL: Characterization of hypoxia-inducible factor l and regulation of DNA binding activity by hypoxia. J Biol Chem. 268:21513–21518. 1993.PubMed/NCBI
16	Ferenci P, Fried M, Labrecque D, Bruix J, Sherman M, Omata M, Heathcote J, Piratsivuth T, Kew M, Otegbayo JA, et al: Hepatocellular carcinoma (HCC): A global perspective. J Clin Gastroenterol. 44:239–245. 2010. View Article : Google Scholar : PubMed/NCBI
17	Da MX, Wu XT, Wang J, Guo TK, Zhao ZG, Luo T, Zhang MM and Qian K: Expression of cyclooxygenase-2 and vascular endothelial growth factor-C correlates with lymphangiogenesis and lymphatic invasion in human gastric cancer. Arch Med Res. 39:92–99. 2008. View Article : Google Scholar : PubMed/NCBI
18	Martínez A: A new family of angiogenic factors. Cancer Lett. 236:157–163. 2006. View Article : Google Scholar : PubMed/NCBI
19	Jakob C, Sterz J, Zavrski I, Heider U, Kleeberg L, Fleissner C, Kaiser M and Sezer O: Angiogenesis in multiple myeloma. Eur J Cancer. 42:1581–1590. 2006. View Article : Google Scholar : PubMed/NCBI
20	Pang RW, Joh JW, Johnson PJ, Monden M, Pawlik TM and Poon RT: Biology of hepatocellular carcinoma. Ann SurgOncol. 15:962–971. 2008.
21	Barr MP, Bouchier-Hayes DJ and Harmey JJ: Vascular endothelial growth factor is an autocrine survival factor for breast tumour cells under hypoxia. Int J Oncol. 32:41–48. 2008.PubMed/NCBI
22	Tzao C, Lee SC, Tung HJ, Hsu HS, Hsu WH, Sun GH, Yu CP, Jin JS and Cheng YL: Expression of hypoxia-inducible factor (HIF)-1alpha and vascular endothelial growth factor (VEGF)-D as outcome predictors in resected esophageal squamous cell carcinoma. Dis Markers. 25:141–148. 2008. View Article : Google Scholar : PubMed/NCBI
23	Lin C, McGough R, Aswad B, Block JA and Terek R: Hypoxia induces HIF-1alpha and VEGF expression in chondrosarcoma cells and chondrocytes. J Orthop Res. 22:1175–1181. 2004. View Article : Google Scholar : PubMed/NCBI
24	Kaelin WG Jr: How oxygen makes its presence felt. Genes Dev. 16:1441–1445. 2002. View Article : Google Scholar : PubMed/NCBI
25	Liu Y, Cox SR, Morita T and Kourembanas S: Hypoxia regulates vascular endothelial growth factor gene expression in endothelial cells. Identification of a 5′ enhancer. Circ Res. 77:638–643. 1995. View Article : Google Scholar : PubMed/NCBI
26	Fukumura D and Jain RK: Tumor microvasculature and microenvironment: Targets for anti-angiogenesis and normalization. Microvasc Res. 74:72–84. 2007. View Article : Google Scholar : PubMed/NCBI
27	Liu S, Yu M, He Y, Xiao L, Wang F, Song C, Sun S, Ling C and Xu Z: Melittin prevents liver cancer cell metastasis through inhibition of the Rac1-dependent pathway. Hepatology. 47:1964–1973. 2008. View Article : Google Scholar : PubMed/NCBI
28	Zhao Y, Li XJ, Sui X, Tang XJ, Qin H and Ren H: Expression and significance of PCNA and Caspase-3 in the tissue of lung cancer. Xi Bao Yu Fen ZiMian Yi XueZa Zhi. 26:154–156. 2010.(In Chinese).
29	Yang XH and Zou L: Dual functions of DNA replication forks in checkpoint signaling and PCNA ubiquitination. Cell Cycle. 8:191–194. 2009. View Article : Google Scholar : PubMed/NCBI
30	Shen H, Feng G, Cui J, Du Q, Qin Y, Cai J, Shen L and Zhu Y: Clinical implications of serum hypoxia inducible factor-1á and vascular endothelial growth factor inlung cancer. Tumori. 101:404–411. 2015. View Article : Google Scholar : PubMed/NCBI
31	Folkman J: Tumor angiogenesis: Therapeutic implications. N Engl J Med. 285:1182–1186. 1971. View Article : Google Scholar : PubMed/NCBI
32	Folkman J: Angiogenesis: An organizing principle for drug discovery? Nat Rev Drug Discov. 6:273–286. 2007. View Article : Google Scholar : PubMed/NCBI
33	Ng KT, Guo DY, Cheng Q, Geng W, Ling CC, Li CX, Liu XB, Ma YY, Lo CM, Poon RT, et al: A garlic derivative, S-allylcysteine (SAC), suppresses proliferation and metastasis of hepatocellular carcinoma. PLoS ONE. 7:e316552012. View Article : Google Scholar : PubMed/NCBI
34	Wang L, Tang ZY, Qin LX, Wu XF, Sun HC, Xue Q and Ye SL: High-dose and long-term therapy with interferon-alfa inhibits tumor growth and recurrence in nude mice bearing human hepatocellular carcinoma xenografts with high metastatic potential. Hepatology. 32:43–48. 2000. View Article : Google Scholar : PubMed/NCBI
35	Bremnes RM, Camps C and Sirera R: Angiogenesis in non-small cell lung cancer: The prognostic impact of neoangiogenesis and the cytokines VEGF and bFGF in tumours and blood. Lung Cancer. 51:143–158. 2006. View Article : Google Scholar : PubMed/NCBI
36	Liao M, Wang H, Lin Z, Feng J and Zhu D: Vascular endothelial growth factor and other biological predictors related to the postoperative survival rate on non-small cell lung cancer. Lung Cancer. 33:125–132. 2001. View Article : Google Scholar : PubMed/NCBI
37	Ushijima C, Tsukamoto S, Yamazaki K, Yoshino I, Sugio K and Sugimachi K: High vascularity in the peripheral region of non-small cell lung cancer tissue is associated with tumor progression. Lung Cancer. 34:233–241. 2001. View Article : Google Scholar : PubMed/NCBI